Back

Timing of sacubitril/valsartan initiation and cardiovascular outcomes in anthracycline-treated cancer patients

29 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Refining cardiotoxicity risk in cardio-oncology Cardio-Oncology ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ivan Rafael Figueroa Baez

San Juan City Hospital, San Juan (Puerto Rico)

3 More presentations in this session

Presentation thumbnail
Risk factors and comorbidities of immune checkpoint inhibitor-associated myocarditis
Miss T. Paul (New Orleans, US)
Abstract Slides Video
Presentation thumbnail
Comparison of cardiovascular and metabolic profiles in lorlatinib vs. other ALK inhibitors in global network
Doctor S. Wang (Tainan, TW)
Abstract Slides Video
Presentation thumbnail
Cardioprotective effects of sacubitril/valsartan according to baseline cardiovascular risk during adjuvant breast cancer therapy: a randomized placebo-controlled trial
Mrs M. Gynnild (Trondheim, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Refining cardiotoxicity risk in cardio-oncology

The Event

Event poster

ESC Congress 2026

29 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Myocardial work derived from myocardial stiffness and strain in childhood cancer survivors treated with high-dose anthracycline chemotherapy
29 August 2026
thumbnail
Congress Presentation
Prognostic impact of LV contractility in patients treated with sacubitril/valsartan for heart failure with reduced ejection fraction
28 August 2026
thumbnail
Congress Presentation
National trends and in-hospital outcomes of tricuspid valve surgery in Germany from 2011 to 2023
30 August 2026
thumbnail
Congress Presentation
Bempedoic acid for LDL-cholesterol management in patients with and without diabetes: insights from the MILOS study
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources